Clinical TrialJun 8, 2026, 06:01 AM
Shattuck Labs SL-325 Phase 1 Data Positive; Low Immunogenicity
AI Summary
Shattuck Labs announced positive Phase 1 clinical trial data for its lead DR3 blocking antibody candidate, SL-325, in healthy volunteers. The trial demonstrated a potentially best-in-mechanism immunogenicity profile with only 3.7% of participants developing antidrug antibodies, complete and durable blockade of TL1A binding to DR3, and a favorable safety profile. Based on these results, the company expects to initiate the RECEPTIVE-CD1 Phase 2b clinical trial for SL-325 in patients with Crohn's disease in the third quarter of 2026. Additionally, Shattuck's bispecific candidate, SL-846, is undergoing IND-enabling studies, with Phase 1 initiation anticipated in the first half of 2027.
Key Highlights
- SL-325 Phase 1 trial showed only 3.7% of participants developed antidrug antibodies.
- Complete blockade of TL1A binding to DR3 expected for over 3 months at doses of 1 mg/kg and higher.
- SL-325 was well tolerated with a favorable safety profile; no serious treatment-emergent adverse events.
- No evidence of DR3 agonism was observed with SL-325.
- RECEPTIVE-CD1 Phase 2b clinical trial for SL-325 in Crohn's disease expected to initiate in Q3 2026.
- Lead bispecific product candidate, SL-846, Phase 1 initiation expected in H1 2027.
Price Impact
More from STTK